Linkedin
RLS logo_header
Linkedin

Promising Early Efficacy and Safety Data for AVA6000 in the Ph 1a Dose Escalation and Ongoing Enrollment in the Ph 1b Expansion Cohorts Announced

Christina Coughlin, CEO of Avacta Therapeutics commented, “We are very pleased to advance to the expansion cohorts in the AVA6000 trial in these three indications with high unmet need.  Our development of AVA6000 is proceeding according to plans and today’s new data demonstrate the durability of the responses we have observed in the SGC indication.  We believe that AVA6000 has an important role to play in the clinic, given our preliminary efficacy data and the large commercial market size of conventional doxorubicin”

Read the full story on "Promising Early Efficacy and Safety Data for AVA6000 in the Ph 1a Dose Escalation and Ongoing Enrollment in the Ph 1b Expansion Cohorts Announced"

Share:

More News

FDA Grants Fast Track Designation for TRE-515 in Combination with KRAS G12C Inhibitors for the Treatment of NSCLC

“Fast Track designation in lung cancer represents an important milestone for TRE-515 and further validates our strategy of combining dCK inhibition with targeted cancer therapies,” said Dr. Ken Schultz, Trethera Chairman and CEO. “KRAS G12C inhibitors have transformed the NSCLC treatment landscape, but resistance and incomplete responses remain major challenges.

Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million

“AvenCell has built a differentiated cell therapy platform that brings together CRISPR-engineered allogeneic CAR-T technology with a unique switchable CAR approach designed to provide greater control over CAR-T activity,” said Todd Davis, CEO of Ligand. “We believe the combination of these technologies, together with the encouraging clinical data generated to

First Patient Enrolled in Global Ph 3 Trial of Cadonilimab vs Nivolumab in 1L Gastric Cancer

“Advanced gastric cancer is characterized by substantial biological and clinical heterogeneity. Previous studies have shown that the magnitude of benefit from PD-1 inhibitor therapy is closely associated with PD-L1 expression, and that there remains room to further improve outcomes, particularly in patients with low PD-L1 expression. How to broaden the

Giredestrant combination significantly improved PFS in ER-positive advanced breast cancer in Ph 3 evERA; data published in The NEJM

“The evERA results represent an important step forward for people with ER-positive advanced breast cancer and underscore the potential for giredestrant to help address the challenge of disease progression in this setting,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Together with the